Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025

Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

View Full Paper
Ask AI
Bookmark
Share

Authors

ZTZhenghai TangMZMing‐Chao ZhongJQJin Qian

Discussion

Loading...

Member takes

Overview

Cis binding of SIRPα with CD18 limits phagocytosis in macrophages, suggesting new immunotherapy strategies.

Key Points

  • The interaction of SIRPα and CD18 hinders macrophage activation and phagocytosis, impacting anti-cancer responses.
  • Blockade of both SIRPα-CD18 and SIRPα-CD47 significantly enhances phagocytosis and reduces tumor growth in vivo.
  • SIRPα mediates effects both through CD47 engagement and directly interacting with CD18 on macrophage surfaces.
  • This study reveals a dual mechanism that inhibitory checkpoints use to suppress immune responses, influencing therapy design.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68d4506b31b076d99fa57601https://doi.org/10.1101/2025.09.10.675342
View Full Paper
Ask AI
Bookmark
Share